These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors? Miura S; Saku K J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856 [No Abstract] [Full Text] [Related]
5. Future of cholesteryl ester transfer protein inhibitors. Rader DJ; deGoma EM Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575 [TBL] [Abstract][Full Text] [Related]
6. HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin. Olsson AG Nutr Metab Cardiovasc Dis; 2010 Oct; 20(8):553-7. PubMed ID: 20739153 [TBL] [Abstract][Full Text] [Related]
7. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit. Taylor J Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754 [No Abstract] [Full Text] [Related]
8. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice]. Olsson AG; Nilsson PM Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786 [No Abstract] [Full Text] [Related]
9. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Oram JF; Heinecke JW Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780 [No Abstract] [Full Text] [Related]
11. HDL- cholesterol: a nut too hard to crack? Kaski JC Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352 [No Abstract] [Full Text] [Related]
12. Learning lessons from Pfizer's $800 million failure. Nat Rev Drug Discov; 2011 Mar; 10(3):163-4. PubMed ID: 21358723 [No Abstract] [Full Text] [Related]
13. Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal? Luft FC J Mol Med (Berl); 2006 Aug; 84(8):625-7. PubMed ID: 16855847 [No Abstract] [Full Text] [Related]
14. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Bajnok L Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322 [TBL] [Abstract][Full Text] [Related]
15. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Howard WJ Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890 [TBL] [Abstract][Full Text] [Related]
16. Lipid disorders. Kole LA JAAPA; 2009 Nov; 22(11):54-5. PubMed ID: 19999177 [No Abstract] [Full Text] [Related]
17. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Niesor EJ Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074 [TBL] [Abstract][Full Text] [Related]
18. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein? Duriez P Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843 [No Abstract] [Full Text] [Related]
19. HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Lange RA; Lindsey ML Eur Heart J; 2008 Nov; 29(22):2708-9. PubMed ID: 18957471 [No Abstract] [Full Text] [Related]